MUPIROCIN (mupirocin) by Ichnos Glenmark Innovation is [see microbiology ()]. Approved for secondarily infected traumatic skin lesions (up to 10 cm in length, 100 cm in area) due to susceptible isolates of staphylococcus aureus, streptococcus pyogenes. First approved in 2021.
Drug data last refreshed 21h ago
[see Microbiology ()].
Worked on MUPIROCIN at Ichnos Glenmark Innovation? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Mupirocin to Reduce Staphylococcus Aureus Colonization in Infants Hospitalized in a NICU
Study to Assess Eradication of Nasal Carriage of Staphylococcus Aureus (SA) With Mupirocin (Bactroban 2% Nasal Ointment)
Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants
Impact of Mupirocin Decolonization on the Nasal Microbiome
Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin